BusinessFrontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes: ResearchMozBy Nasdaq OMXSep 14, 2016, 1:03 PM UTC
